Financial

RTI Surgical Announces Second Quarter 2018 Results

August 02, 2018

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical, Inc. (Nasdaq: RTIX), a global surgical implant company, reported operating results for the second quarter of 2018.

“Our team is sustaining the momentum generated over the past 18 months, as evidenced by our positive operational and financial performance this quarter,” said Camille Farhat, chief executive officer. “As anticipated in our previously issued guidance, our OEM franchise continues to contribute attractive growth, which we believe demonstrates the importance of the changes we implemented in 2017 and the value of our diverse portfolio. Our current operational excellence priorities, focused primarily on the cost of tissue processing, began to positively impact our cost of sales this quarter, providing significant margin and adjusted EBITDA improvements. Our efforts to date are encouraging and we believe that we remain well positioned to deliver on our commitments in 2018 and beyond.”

Farhat added, “As we enter the second half of the year, we continue to make significant strides in our strategic transformation. Following the recent owned agency transition announcement, we have further reduced the complexity of our operations through the reduction of vertical integration and increased focus on our strength in tissue processing. We believe we maintain strong partnerships with the organ procurement community that, in our opinion, ensure that we can continue to expand the number of patients served with our differentiated allograft products. With the implementation of our operational excellence initiatives well underway, we are starting to see the positive outcomes in our financial results, and I am proud of the ongoing efforts of many people across the Company. Also, we are encouraged by the progress demonstrated by the team managing the Zyga acquisition and integration, which exemplify our endeavors to accelerate growth. In light of this progress, I am focused on reinvigorating the R&D pipeline and pursuing attractive deals at logical valuations.”

Second Quarter 2018

RTI’s worldwide revenues for the second quarter of 2018 were $70.7 million, down slightly compared with $72.1 million during the same period for the prior year. Excluding a $3.7 million reduction from the sale of substantially all the assets of the cardiothoracic closure business completed in August 2017, our total revenues increased $2.2 million, or 3.3%. Gross profit for the second quarter of 2018 was $30.0 million, inclusive of a $6.8 million charge for the write-off of excess inventory related to decreased distributions of our map3® implant and the purchase accounting step-up of Zyga inventory. To partially offset the impact of the decreased distribution of map3® implant we signed a distribution agreement with Aziyo Biologics, Inc., to supplement our biologics portfolio with an alternative allograft stem cell product. Excluding the excess inventory charge and purchase accounting impact, our Adjusted Gross Profit for the second quarter of 2018 was $36.8 million or 52.1% of revenues, compared to $37.0 million, or 51.3% of revenues, in the second quarter of 2017.

During the second quarter of 2018, RTI incurred non-recurring pre-tax charges to support the ongoing strategic transformation of the business. The company incurred $4.5 million in asset impairment and abandonment charges related to decreased distribution of our map3® implant During the second quarter of 2017, the company incurred $3.4 million of non-recurring pre-tax charges.

Net loss applicable to common shares was $6.4 million, or $0.10 per fully diluted common share in the second quarter of 2018, compared to a net loss applicable to common shares of $2.6 million, or $0.04 per fully diluted common share in the second quarter of 2017. As outlined in the reconciliation tables that follow, excluding the impact of the various non-recurring charges, Adjusted Net Income applicable to common shares was $2.0 million, or $0.03 per fully diluted common share in the second quarter of 2018.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA), for the second quarter of 2018 was $9.1 million, or 13% of revenues compared with $8.3 million, inclusive of $1.2 million of EBITDA related to the cardiovascular closure business, or 11% of revenues for the second quarter of 2017. The increase in Adjusted EBITDA is primarily driven by the reduction in operating expenses associated with efforts to reduce complexity and increase operational excellence implemented during 2017.

Fiscal 2018 Outlook

Based on our recent financial results and current business outlook, the Company is reiterating financial guidance for 2018, originally issued on January 5, 2018:

  • The Company expects full year revenues in the range of $280 million and $290 million.
  • The Company expects full year Adjusted EBITDA to be in the range of $32 million to $38 million.

The Company noted the following assumptions are included in its guidance:

  • Relatively stable market conditions and regulatory environment;
  • Positive revenue contribution from the acquisition of Zyga Technology – announced January 4, 2018;
  • Ongoing positive impact of efforts to reduce complexity and implement operational excellence; and
  • Continued demand of map3® cellular allogeneic bone graft or alternative allograft stem cell product.

Conference Call

RTI will host a conference call and audio webcast at 9:00 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical, Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic and trauma procedures and are distributed in more than 40 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements made in this communication about our positive operational and financial performance, the continued contribution of the OEM franchise to RTI’s growth, the impact of operational priorities on costs and their impact on RTI’s financial performance, RTI’s ability to meet its commitments, the implementation of RTI’s strategic initiatives, the reduction in complexity of RTI’s operations, RTI’s ability to maintain partnerships in the organ procurement community, RTI’s ability to expand the number of patients it is able to serve, the integration of Zyga’s operations, anticipated financial results, growth rates, new product introductions, and future operational improvements. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including RTI’s ability to reduce inventory, manage expenses and accomplish its goals and strategies, the quality of the new product offerings from RTI, general economic conditions, as well as those within RTI’s industry, RTI’s ability to integrate acquisitions into existing operations, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2017 and other filings with the Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

RTI SURGICAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)
Three months ended Six months ended
June 30, June 30,
2018 2017 2018 2017
Revenues $ 70,685 $ 72,120 $ 140,575 $ 142,059
Costs of processing and distribution 40,645 35,157 76,853 69,317
Gross profit 30,040 36,963 63,722 72,742
Expenses:
Marketing, general and administrative 29,266 29,496 57,655 59,167
Research and development 3,270 3,740 6,691 7,428
Severance and restructuring costs 3,400 884 7,803
Asset impairment and abandonments 4,515 4,644
Acquisition and integration expenses 800
Total operating expenses 37,051 36,636 70,674 74,398
Operating (loss) income (7,011 ) 327 (6,952 ) (1,656 )
Total other expense – net (1,151 ) (990 ) (1,926 ) (1,789 )
Loss before income tax provision (8,162 ) (663 ) (8,878 ) (3,445 )
Income tax benefit (provision) 2,702 (1,026 ) 2,453 (116 )
Net loss (5,460 ) (1,689 ) (6,425 ) (3,561 )
Convertible preferred dividend (981 ) (924 ) (1,947 ) (1,834 )
Net loss applicable to common shares $ (6,441 ) $ (2,613 ) $ (8,372 ) $ (5,395 )
Net loss per common share – basic $ (0.10 ) $ (0.04 ) $ (0.13 ) $ (0.09 )
Net loss per common share – diluted $ (0.10 ) $ (0.04 ) $ (0.13 ) $ (0.09 )
Weighted average shares outstanding – basic 63,405,708 58,935,786 63,400,737 58,715,791
Weighted average shares outstanding – diluted 63,405,708 58,935,786 63,400,737 58,715,791
RTI SURGICAL, INC. AND SUBSIDIARIES
Reconciliation of Net Loss Applicable to Commons Shares to Adjusted EBITDA
(Unaudited, in thousands)
Three Months Six Months
Ended June 30, Ended June 30,
2018 2017 2018 2017
Net loss applicable to common shares $ (6,441 ) $ (2,613 ) $ (8,372 ) $ (5,395 )
Interest expense, net 771 915 1,595 1,734
(Benefit) provision for income taxes (2,702 ) 1,026 (2,453 ) 116
Depreciation 2,524 2,652 5,147 5,324
Amortization of intangible assets 960 909 1,921 1,805
EBITDA (4,888 ) 2,889 (2,162 ) 3,584
Reconciling items impacting EBITDA
Preferred dividend 981 924 1,947 1,834
Non-cash stock based compensation 1,290 974 2,570 1,808
Foreign exchange gain 71 75 22 55
Other reconciling items *
Inventory write-off 6,559 7,582
Inventory purchase price adjustment 250 456
Severance and restructuring costs 3,400 884 7,470
Loss on extinguishment of debt 309 309
Asset impairment and abandonments 4,515 4,515
Acquisition and integration expenses 800
Adjusted EBITDA $ 9,087 $ 8,262 $ 16,923 $ 14,751
Adjusted EBITDA as a percent of revenues 13 % 11 % 12 % 10 %
* See explanations in Use of Non-GAAP Financial Measures section later in this release.
RTI SURGICAL, INC. AND SUBSIDIARIES
Reconciliation of Net Loss Applicable to Common Shares and Net Loss Per Diluted Share to
Adjusted Net Income Applicable to Common Shares and Adjusted Net Income Per Diluted Share
(Unaudited, in thousands except per share data)
Three Months Ended
June 30, 2018 June 30, 2017
Net Net
(Loss) Income Amount (Loss) Income Amount
Applicable to Per Diluted Applicable to Per Diluted
Common Shares Share Common Shares Share
As reported $ (6,441 ) $ (0.10 ) $ (2,613 ) $ (0.04 )
Severance and restructuring costs 3,400 0.06
Asset impairment and abandonments 4,515 0.07
Inventory purchase price adjustment 250 0.00
Loss on extinguishment of debt 309 0.00

Inventory obsolescence and reserve charge

6,559 0.10
Tax effect on adjustments (3,161 ) (0.05 ) 178 0.00
Adjusted * $ 2,031 $ 0.03 $ 965 $ 0.02
Six Months Ended
June 30, 2018 June 30, 2017
Net Net
(Loss) Income Amount (Loss) Income Amount
Applicable to Per Diluted Applicable to Per Diluted
Common Shares Share Common Shares Share
As reported $ (8,372 ) $ (0.13 ) $ (5,395 ) $ (0.09 )
Severance and restructuring costs 884 0.01 7,803 0.13
Asset impairment and abandonments 4,515 0.07
Inventory purchase price adjustment 456 0.01
Loss on extinguishment of debt 309 0.00

Inventory obsolescence and reserve charge

7,582 0.12
Acquisition and integration expenses 800 0.01
Tax effect on adjustments (3,654 ) (0.06 ) (1,304 ) (0.02 )
Adjusted * $ 2,520 $ 0.04 $ 1,104 $ 0.02
* See explanations in Use of Non-GAAP Financial Measures section later in this release.
Amount Per Diluted Share may not foot due to rounding.

Use of Non-GAAP Financial Measures

To supplement the Company’s unaudited condensed consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures that exclude certain amounts, including EBITDA, Adjusted EBITDA, Adjusted Net Income Applicable to Common Shares, Adjusted Net Income per Common Share – Diluted and Adjusted Gross Profit. The calculation of the tax effect on the adjustments between GAAP net loss applicable to common shares and non-GAAP net income applicable to common shares is based upon our estimated annual GAAP tax rate, adjusted to account for items excluded from GAAP net loss applicable to common shares in calculating Adjusted Net Income Applicable to Common Shares-Diluted. A reconciliation of the non-GAAP financial measures to the corresponding GAAP measures is included in the tables listed above.

The following is an explanation of the adjustments that management excluded as part of adjusted measures for the three and six months ended June 30, 2018 and 2017 as well as the reason for excluding the individual items:

Severance and restructuring costs – This adjustment represents costs relating to the reduction of our organizational structure. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Asset impairment and abandonments – This adjustment represents an asset impairment and abandonments related to decreased distributions of our map3® implant. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Acquisition and integration expenses – This adjustment represents charges relating to acquisition and integration expenses due to the purchase of Zyga. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Inventory obsolescence and reserve charge – This adjustment represents charges relating to inventory obsolescence due to the rationalization of our international distribution infrastructure and an inventory reserve charge related to decreased distributions of our map3® implant. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Inventory purchase price adjustment – This adjustment represents the purchase price effects of acquired Zyga inventory that was sold during the six months ended June 30, 2018. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Loss on extinguishment of debt – This adjustment represents costs relating to refinancing our debt. Management removes the amount of these costs from our operating results to supplement a comparison to our past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA, Adjusted Net Income Applicable to Common Shares, Adjusted Net Income per Common Share – Diluted, and Adjusted Gross Profit should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting EBITDA, Adjusted EBITDA, Adjusted Net Income Applicable to Common Shares, Adjusted Net Income per Common Share – Diluted and Adjusted Gross Profit in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making. The Company further believes that providing this information better enables the Company’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Revenues
(Unaudited, in thousands)
For the Three Months Ended For the Six Months Ended
June 30, June 30,
2018 2017 2018 2017
Revenues: (In thousands)
Spine $ 18,934 $ 19,419 $ 38,197 $ 39,757
Sports 14,190 14,453 27,625 29,129
OEM 31,170 27,983 61,290 53,125
International 6,391 6,592 13,463 13,224
Cardiothoracic 3,673 6,824
Total revenues $ 70,685 $ 72,120 $ 140,575 $ 142,059
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
June 30, December 31,
2018 2017
Assets
Cash $ 14,246 $ 22,381
Accounts receivable – net 45,576 35,081
Inventories – net 101,022 111,927
Prepaid and other assets 8,038 16,285
Total current assets 168,882 185,674
Property, plant and equipment – net 76,838 79,564
Goodwill 64,863 46,242
Other assets – net 36,910 34,426
Total assets $ 347,493 $ 345,906
Liabilities and Stockholders’ Equity
Accounts payable $ 14,797 $ 18,252
Accrued expenses and other current liabilities 28,934 30,478
Current portion of long-term obligations 4,268
Total current liabilities 43,731 52,998
Deferred revenue 3,155 3,741
Long-term liabilities 58,571 43,507
Total liabilities 105,457 100,246
Preferred stock 65,961 63,923
Stockholders’ equity:
Common stock and additional paid-in capital 425,544 425,132
Accumulated other comprehensive loss (6,850 ) (6,329 )
Accumulated deficit (242,619 ) (237,066 )
Total stockholders’ equity 176,075 181,737
Total liabilities and stockholders’ equity $ 347,493 $ 345,906
RTI SURGICAL, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
Three Months Six Months
Ended June 30, Ended June 30,
2018 2017 2018 2017
Cash flows from operating activities:
Net loss $ (5,460 ) $ (1,689 ) $ (6,425 ) $ (3,561 )
Adjustments to reconcile net loss to net cash
provided by operating activities:
Depreciation and amortization expense 3,484 3,561 7,068 7,129
Stock-based compensation 1,290 974 2,570 1,808
Amortization of deferred revenue (1,218 ) (1,186 ) (2,435 ) (2,460 )
Other items to reconcile to net cash
(used in) provided by operating activities 12,731 (624 ) 8,600 7,697
Net cash provided by operating activities 10,827 1,036 9,378 10,613
Cash flows from investing activities:
Purchases of property, plant and equipment (1,738 ) (3,877 ) (3,856 ) (7,160 )
Patent and acquired intangible asset costs (398 ) (1,526 ) (728 ) (1,845 )
Acquisition of Zyga Technology (21,000 )
Net cash used in investing activities (2,136 ) (5,403 ) (25,584 ) (9,005 )
Cash flows from financing activities:
Proceeds from long-term obligations 54,425 2,000 74,425 4,000
Payments on long-term obligations (61,625 ) (3,125 ) (66,750 ) (7,375 )
Other financing activities (991 ) 1,467 403 1,433
Net cash (used in) provided by financing activities (8,191 ) 342 8,078 (1,942 )
Effect of exchange rate changes on cash and cash equivalents (66 ) 102 (7 ) 160
Net increase (decrease) in cash and cash equivalents 434 (3,923 ) (8,135 ) (174 )
Cash and cash equivalents, beginning of period 13,812 17,598 22,381 13,849
Cash and cash equivalents, end of period $ 14,246 $ 13,675 $ 14,246 $ 13,675

Contacts

RTI Surgical, Inc.
Media Contact:
Molly Poarch, +1-224-287-2661
mpoarch@rtix.com
or
Investor Contact:
Nathan Elwell, +1-847-530-0249
nelwell@lincolnchurchilladvisors.com

Tags

Mason Krell

Mason began his career in the Orthopedic Industry in 2017 when he joined The De Angelis Group as a Research Manager. He has developed a strong network within the industry and is very dedicated to helping companies maximize opportunities and disrupt markets.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close